[ET Net News Agency, 30 December 2019] Genscript Biotech Corporation (01548) said its
subsidiary GenScript (Hong Kong) Limited (GS HK) has entered into an investment agreement
with Zhenjiang New Area Management Committee (the Zhenjiang Committee).
Zhenjiang Committee shall provide Genscript HK with three factories of 20,000m2 in total
at nil rent for five years (from 2021 to 2025). GS HK will invest a total of RMB180
million by contributing fixed assets and cash for the construction of factories, office
buildings and other storage facilities for the expansion of (i) the molecular biology
production capacity, (ii) the research laboratory of cell therapy vector plasmid
technology, and (iii) peptide GMP (good manufacturing practices) business. (RC)